EcoDrugPlus

Phosphodiesterase 4c

Ensembl ID : ENSPCTG00005021377
Gene Symbol: PDE4C
1 Cross references
269 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSPCTG00005009332
Gene Symbol: PDE4D
4 Cross references
244 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSPCTG00005007066
Gene Symbol: PDE5A
3 Cross references
220 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSPCTG00005003278
Gene Symbol: PDE7B
3 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSPCTG00005012834
Gene Symbol: PDE9A
1 Cross references
280 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPCTG00005014702
Gene Symbol: PIK3R1
3 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSPCTG00005021628
Gene Symbol: PIK3R2
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPCTG00005009909
Gene Symbol: PIK3R5
3 Cross references
254 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSPCTG00005015528
Gene Symbol: PLA2G5
1 Cross references
116 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSPCTG00005012124
Gene Symbol: PLA2G10
2 Cross references
249 Possible Orthologues:

Plasminogen

Ensembl ID : ENSPCTG00005003046
Gene Symbol: LOC102979031
2 Cross references
240 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSPCTG00005020483
Gene Symbol: PLAT
1 Cross references
204 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).